Hypofractionated WPRT for Endometrial Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Endometrial CancerHypofractionated WPRT - Radiation
Eligibility
18+
Female
What conditions do you have?
Select

Study Summary

This trial is testing whether a lower dose of radiation therapy spread out over a longer period of time is as effective at treating endometrial cancer as the standard higher dose given in a shorter timeframe.

Eligible Conditions
  • Endometrial Cancer

Treatment Effectiveness

Study Objectives

2 Primary · 2 Secondary · Reporting Duration: 3 months

3 months
Impact of hypofractionated WPRT on patient quality of life using the Functional Assessment of Cancer Therapy-Endometrial version 4.0.
Maximum tolerated dose per fraction (MTDF) of hypofractionated, isoeffective whole pelvis radiation regimens for post-operative treatment of endometrial cancer through CTCAE data and gastrointestinal PRO-CTCAE data.
Patient compliance with hypofractionated WPRT, as defined by how many patients are able to complete WPRT without a break in treatment.
Safety profile of hypofractionated, isoeffective whole pelvis radiation regimens for post-operative treatment of endometrial cancer using CTCAE version 5.0 and Patient Reported Outcome-CTCAE.

Trial Safety

Trial Design

1 Treatment Group

Hypofractionated Whole-Pelvis Radiotherapy
1 of 1

Experimental Treatment

15 Total Participants · 1 Treatment Group

Primary Treatment: Hypofractionated WPRT · No Placebo Group · N/A

Hypofractionated Whole-Pelvis Radiotherapy
Radiation
Experimental Group · 1 Intervention: Hypofractionated WPRT · Intervention Types: Radiation

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 3 months

Who is running the clinical trial?

Teresa MeierLead Sponsor
Teresa Meier, MDPrincipal Investigator - University of Cincinnati
University of Cincinnati Medical Center

Eligibility Criteria

Age 18+ · Female Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Patients who have had a total hysterectomy and bilateral salpingo-oophorectomy with or without pelvic and/or para-aortic lymph node dissection/sampling or sentinel lymph node (SLN) dissection are eligible to participate in the study.
Patients with histologically confirmed stage I, II, or III endometrial cancer who require pelvic radiation therapy as determined by their treating radiation oncologist and/or gynecologic oncologist
The ability to understand the study and the willingness to sign a written document that confirms that understanding.
Age must be 18 years or older.
The person has a very good performance status, as indicated by a Karnofsky score of at least 60%.
People who have a cancer that is not going to interfere with the safety or effectiveness of the new treatment can participate in this trial.